Computational identification of novel natural inhibitors of glucagon receptor for checking type II diabetes mellitus

BMC Bioinformatics

Volumn 15, Issue 16, 2014, Pages

  Grover, Sonam ^a   Dhanjal, Jaspreet Kaur ^a   Goyal, Sukriti ^b   Grover, Abhinav ^c   Sundar, Durai ^a  

^a INDIAN INSTITUTE OF TECHNOLOGY DELHI   (India)

^b BANASTHALI UNIVERSITY   (India)

^c JAWAHARLAL NEHRU UNIVERSITY   (India)

Author keywords

7 transmembrane Domain; Docking; Glucagon Receptor; Natural Inhibitor; Virtual Screening

Indexed keywords

ACTIVATION ANALYSIS; BINDING ENERGY; DOCKING; GLUCOSE; LIGANDS; MOLECULAR DYNAMICS; MOLECULES; PEPTIDES;

COMPUTATIONAL IDENTIFICATION; GLUCAGON RECEPTOR; LIGAND-BINDING RESIDUES; MOLECULAR DYNAMICS SIMULATIONS; NATURAL INHIBITOR; TRANS-MEMBRANE DOMAINS; TYPE II DIABETES MELLITUS; VIRTUAL SCREENING;

BINS;

BETA ALANINE; DRUG; GLUCAGON; GLUCAGON RECEPTOR; GLUCOSE BLOOD LEVEL; N-((4-(1-(3-(3,5-DICHLOROPHENYL)-5-(6-METHOXYNAPHTHALEN-2-YL)-1H-PYRAZOL-1-YL)ETHYL)PHENYL)CARBONYL)-BETA-ALANINE; PEPTIDE LIBRARY; PROTEIN BINDING; PYRAZOLE DERIVATIVE;

ANALOGS AND DERIVATIVES; ANALYSIS; ANTAGONISTS AND INHIBITORS; BIOLOGY; CHEMISTRY; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; HIGH THROUGHPUT SCREENING; HUMAN; LIVER; METABOLISM; MOLECULAR DYNAMICS; PEPTIDE LIBRARY; PROCEDURES; PROTEIN CONFORMATION;

BETA-ALANINE; BLOOD GLUCOSE; COMPUTATIONAL BIOLOGY; DIABETES MELLITUS, TYPE 2; GLUCAGON; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; LIVER; MOLECULAR DYNAMICS SIMULATION; PEPTIDE LIBRARY; PHARMACEUTICAL PREPARATIONS; PROTEIN BINDING; PROTEIN CONFORMATION; PYRAZOLES; RECEPTORS, GLUCAGON;

EID: 84961653112     PISSN: None     EISSN: 14712105     Source Type: Journal    
DOI: 10.1186/1471-2105-15-S16-S13     Document Type: Article

References (39)

1. Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, Lin JK, Farzadfar F, Khang YH, Stevens GA: National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet. 2011, 378 (9785): 31-40. 10.1016/S0140-6736(11)60679-X.
2. Lagerstrom MC, Schioth HB: Structural diversity of G protein-coupled receptors and significance for drug discovery. Nat Rev Drug Discov. 2008, 7 (4): 339-357. 10.1038/nrd2518.
3. Hoare SR: Mechanisms of peptide and nonpeptide ligand binding to Class B G-protein-coupled receptors. Drug Discov Today. 2005, 10 (6): 417-427. 10.1016/S1359-6446(05)03370-2.
4. Pal K, Melcher K, Xu HE: Structure and mechanism for recognition of peptide hormones by Class B G-protein-coupled receptors. Acta Pharmacol Sin. 2012, 33 (3): 300-311. 10.1038/aps.2011.170.
5. Ali S, Drucker DJ: Benefits and limitations of reducing glucagon action for the treatment of type 2 diabetes. Am J Physiol Endocrinol Metab. 2009, 296 (3): E415-421.
6. Jiang G, Zhang BB: Glucagon and regulation of glucose metabolism. Am J Physiol Endocrinol Metab. 2003, 284 (4): E671-678. 10.1152/ajpendo.00492.2002.
7. Lee Y, Wang MY, Du XQ, Charron MJ, Unger RH: Glucagon Receptor Knockout Prevents Insulin-Deficient Type 1 Diabetes in Mice. Diabetes. 2011, 60 (2): 391-397. 10.2337/db10-0426.
8. Tan K, Tsiolakis D, Marks V: Effect of Glucagon Antibodies on Plasma-Glucose, Insulin and Somatostatin in the Fasting and Fed Rat. Diabetologia. 1985, 28 (7): 435-440. 10.1007/BF00280887.
9. Sloop KW, Michael MD, Moyers JS: Glucagon as a target for the treatment of Type 2 diabetes. Expert Opin Ther Tar. 2005, 9 (3): 593-600. 10.1517/14728222.9.3.593.
10. Qureshi SA, Candelore MR, Xie D, Yang XD, Tota LM, Ding VDH, Li ZH, Bansal A, Miller C, Cohen SM: A novel glucagon receptor antagonist inhibits glucagon-mediated biological effects. Diabetes. 2004, 53 (12): 3267-3273. 10.2337/diabetes.53.12.3267.
11. Lau J, Behrens C, Sidelmann UG, Knudsen LB, Lundt B, Sams C, Ynddal L, Brand CL, Pridal L, Ling A: New beta-alanine derivatives are orally available glucagon receptor antagonists. J Med Chem. 2007, 50 (1): 113-128. 10.1021/jm058026u.
12. Liang R, Abrardo L, Brady EJ, Candelore MR, Ding V, Saperstein R, Tota LM, Wright M, Mock S, Tamvakopolous C: Design and synthesis of conformationally constrained tri-substituted ureas as potent antagonists of the human glucagon receptor. Bioorg Med Chem Lett. 2007, 17 (3): 587-592. 10.1016/j.bmcl.2006.11.014.
13. Kim RM, Chang J, Lins AR, Brady E, Candelore MR, Dallas-Yang Q, Ding V, Dragovic J, Iliff S, Jiang GQ: Discovery of potent, orally active benzimidazole glucagon receptor antagonists. Bioorg Med Chem Lett. 2008, 18 (13): 3701-3705. 10.1016/j.bmcl.2008.05.072.
14. Madsen P, Kodra JT, Behrens C, Nishimura E, Jeppesen CB, Pridal L, Andersen B, Knudsen LB, Valcarce-Aspegren C, Guldbrandt M: Human Glucagon Receptor Antagonists with Thiazole Cores. A Novel Series with Superior Pharmacokinetic Properties. J Med Chem. 2009, 52 (9): 2989-3000. 10.1021/jm8016249.
15. Mu J, Qureshi SA, Brady EJ, Muise ES, Candelore MR, Jiang GQ, Li ZH, Wu MS, Yang XD, Dallas-Yang Q: Anti-Diabetic Efficacy and Impact on Amino Acid Metabolism of GRA1, a Novel Small-Molecule Glucagon Receptor Antagonist. Plos One. 2012, 7 (11):
16. Estall JL, Drucker DJ: Glucagon and glucagon-like peptide receptors as drug targets. Curr Pharm Design. 2006, 12 (14): 1731-1750. 10.2174/138161206776873671.
17. Yaqub T, Tikhonova IG, Lattig J, Magnan R, Laval M, Escrieut C, Boulegue C, Hewage C, Fourmy D: Identification of determinants of glucose-dependent insulinotropic polypeptide receptor that interact with N-terminal biologically active region of the natural ligand. Mol Pharmacol. 2010, 77 (4): 547-558. 10.1124/mol.109.060111.
18. Miller LJ, Dong M, Harikumar KG, Gao F: Structural basis of natural ligand binding and activation of the Class II G-protein-coupled secretin receptor. Biochem Soc Trans. 2007, 35 (Pt 4): 709-712.
19. Dong MQ, Xu XQ, Ball AM, Makhoul JA, Lam PCH, Pinon DI, Orry A, Sexton PM, Abagyan R, Miller LJ: Mapping spatial approximations between the amino terminus of secretin and each of the extracellular loops of its receptor using cysteine trapping. Faseb J. 2012, 26 (12): 5092-5105. 10.1096/fj.12-212399.
20. Miller LJ, Chen Q, Lam PC, Pinon DI, Sexton PM, Abagyan R, Dong M: Refinement of glucagon-like peptide 1 docking to its intact receptor using mid-region photolabile probes and molecular modeling. J Biol Chem. 2011, 286 (18): 15895-15907. 10.1074/jbc.M110.217901.
21. Dong M, Lam PCH, Pinon DI, Hosohata K, Orry A, Sexton PM, Abagyan R, Miller LJ: Molecular Basis of Secretin Docking to Its Intact Receptor Using Multiple Photolabile Probes Distributed throughout the Pharmacophore. J Biol Chem. 2011, 286 (27): 23888-23899. 10.1074/jbc.M111.245969.
22. Gensure RC, Shimizu N, Tsang J, Gardella TJ: Identification of a contact site for residue 19 of parathyroid hormone (PTH) and PTH-related protein analogs in transmembrane domain two of the type 1 PTH receptor. Mol Endocrinol. 2003, 17 (12): 2647-2658. 10.1210/me.2003-0275.
23. de Graaf C, Rein C, Piwnica D, Giordanetto F, Rognan D: Structure-based discovery of allosteric modulators of two related class B G-protein-coupled receptors. ChemMedChem. 2011, 6 (12): 2159-2169. 10.1002/cmdc.201100317.
24. Siu FY, He M, de Graaf C, Han GW, Yang DH, Zhang ZY, Zhou CH, Xu QP, Wacker D, Joseph JS: Structure of the human glucagon class B G-protein-coupled receptor. Nature. 2013, 499 (7459): 444-+. 10.1038/nature12393.
25. Schrodinger, Maestro, version 9, LLC. 2009, New York, NY, USA
26. Sreeramulu S, Jonker HR, Langer T, Richter C, Lancaster CR, Schwalbe H: The human Cdc37.Hsp90 complex studied by heteronuclear NMR spectroscopy. J Biol Chem. 2009, 284 (6): 3885-3896. 10.1074/jbc.M806715200.
27. Irwin JJ, Raushel FM, Shoichet BK: Virtual screening against metalloenzymes for inhibitors and substrates. Biochemistry. 2005, 44 (37): 12316-12328. 10.1021/bi050801k.
28. Schrodinger, Ligprep, version 2.3, LLC. 2009, New York, NY, USA
29. Halgren TA, Murphy RB, Friesner RA, Beard HS, Frye LL, Pollard WT, Banks JL: Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J Med Chem. 2004, 47 (7): 1750-1759. 10.1021/jm030644s.
30. Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, Repasky MP, Knoll EH, Shelley M, Perry JK: Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem. 2004, 47 (7): 1739-1749. 10.1021/jm0306430.
31. Qian J, Zhu CH, Tang S, Shen AJ, Ai J, Li J, Geng MY, Ding J: alpha2,6-hyposialylation of c-Met abolishes cell motility of ST6Gal-I-knockdown HCT116 cells. Acta Pharmacol Sin. 2009, 30 (7): 1039-1045. 10.1038/aps.2009.84.
32. Sandor M, Kiss R, Keseru GM: Virtual fragment docking by Glide: a validation study on 190 protein-fragment complexes. J Chem Inf Model. 2010, 50 (6): 1165-1172. 10.1021/ci1000407.
33. Guo Z, Mohanty U, Noehre J, Sawyer TK, Sherman W, Krilov G: Probing the alpha-helical structural stability of stapled p53 peptides: molecular dynamics simulations and analysis. Chemical biology & drug design. 2010, 75 (4): 348-359. 10.1111/j.1747-0285.2010.00951.x.
34. Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein ML: Comparison of simple potential functions for simulating liquid water. The Journal of chemical physics. 1983, 79: 926-10.1063/1.445869.
35. Wallace AC, Laskowski RA, Thornton JM: LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein engineering. 1995, 8 (2): 127-134. 10.1093/protein/8.2.127.
36. Xiong Y, Guo J, Candelore MR, Liang R, Miller C, Dallas-Yang Q, Jiang G, McCann PE, Qureshi SA, Tong X: Discovery of a novel glucagon receptor antagonist N-[(4-[(1S)-1-[3-(3, 5-dichlorophenyl)-5-(6-methoxynaphthalen-2-yl)-1H-pyrazol-1-yl]ethyl]phenyl)carbo nyl]-beta-alanine (MK-0893) for the treatment of type II diabetes. J Med Chem. 2012, 55 (13): 6137-6148. 10.1021/jm300579z.
37. Kelly RP GP, Abu-Raddad EJ, Fu H, Lim CN, Prince MJ, Pinaire JA, Loh MT, Deeg MA: Short-term treatment with glucagon receptor antagonist LY2409021 effectively reduces fasting blood glucose and HbA1c in patients with type 2 diabetes mellitus. Diabetes. 2011, 60: A84-
38. QuickProp. version 3.2 edn: Schrödinger. 2009, LLC, New York, NY
39. Runge S, Gram C, Brauner-Osborne H, Madsen K, Knudsen LB, Wulff BS: Three distinct epitopes on the extracellular face of the glucagon receptor determine specificity for the glucagon amino terminus. J Biol Chem. 2003, 278 (30): 28005-28010. 10.1074/jbc.M301085200.